STA: Dupilumab for treating moderate to severe atopic dermatitis after topical treatments

STA: Dupilumab for treating moderate to severe atopic dermatitis after topical treatments 

As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) was invited to critically review the company’s submission related to the clinical and cost-effectiveness of Dupilumab for treating moderate to severe atopic dermatitis after topical treatments. 

Outcome and Translation

This appraisal is now complete. Based on the evidence submitted by the company, and the critique provided by the evidence review group, NICE developed recommendations on the use of Dupilumab for treating moderate to severe atopic dermatitis in adults: Dupilumab for treating moderate to severe atopic dermatitis after topical treatments [ID1048] 

HERU researchers invovled in this project:  Rodolfo Hernández, Maria Dimitrova, Graham Scotland 

External collaborators:  Ramsay, C., Brazzelli, M; Cummins, E; Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).

Publications

Hernández, R., Cruickshank, M., Dimitrova, M., Cooper, D., Aucott, L., Fraser, C., Shimonovich, M., Ormerod, A., Scotland, G. and Brazzelli, M. (2018) Dupilumab for treating adults with moderate to severe atopic dermatitis, (NICE Technology Appraisal Guidance - TA534), Aberdeen HTA Group.